

For clinicians

There is increasing evidence of prescription medication related harms and overdose deaths due to inappropriate prescription and unsanctioned use of opioids and benzodiazepines in Australia.

Recommendation: avoid prescribing a combination of opioid and benzodiazepine medications for patients with acute or chronic pain

- Australian and international guidelines support the avoidance of prescribing a combination of opioid and benzodiazepine medications^{2,3,4,5,6,7}
- It is well-established that concomitant use of opioids with central nervous system depressants such as benzodiazepines or alcohol is associated with increased risk of profound sedation, respiratory depression, coma and death^{2,5}
- Concomitant use of benzodiazepines or other central nervous system depressants further enhances the effects of opioids such as respiratory-depression^{3,4}
- Increased caution is also urged for the prescription of these medications during sleep hours, particularly in older patients or in patients with sleep disorders (such as sleep apnoea)^{3,4}
- The concurrent prescription of opioids and benzodiazepines may be appropriate if a patient has severe acute pain and is also on a long-term, stable low-dose of benzodiazepine medication⁵ or if alternative treatments are inadequate or ineffective²
- When concomitant prescribing does occur, minimum dosage and duration are advised, along with appropriate monitoring for sedation and respiratory problems²

Concerns about combined use of opioids and benzodiazepines in the management of pain

- The combined use of prescription opioids and benzodiazepines is associated with an increased risk of overdose death^{5,6}
- The combined use of these medications can also impair driving and Increasing evidence suggests that use of benzodiazepines in particular is associated with increased risk of road accidents⁸
- According to the Australian Bureau of Statistics, in 2016, an Australian most likely to die from a drug induced death was a middle-aged man misusing multiple prescription medications such as benzodiazepines or oxycodone¹
- Benzodiazepines were present in 663 deaths in 2016, making them the most common drug present in drug induced deaths (36.7%). Moreover, in over 96% of these drug deaths, they were taken with other drugs, including alcohol¹
- Prescription opioids such as oxycodone, morphine and codeine were present in over 30% of drug deaths in 2016¹
- Studies in the United States and Canada have also indicated that combined use of these medications increases overdose risks⁶
- In West Virginia, people who filled an opioid and benzodiazepine prescription were at a 15-fold increase of risk of a drug-related death compared to people who weren't prescribed these medications⁶
- In Canada, the toxicology reports of 60.4% of people who died due to an opioid-related death (and had been prescribed an opioid for non-malignant pain) showed benzodiazepines⁶

Practice point

- Clinicians are advised to obtain a full history of the patient's use of medications and other substances in a non-judgmental manner to develop an individualised pain management plan⁹
- Pain management plans involving opioids should also be developed with an understanding of co-morbidities such as anxiety and depression⁵

- When risk factors such as combined use of benzodiazepines and opioids are identified, pain management plans should reduce the risk of overdose by also providing naloxone⁵
- Patients at increased risk of concomitant prescribing include older adults who are more likely to have been prescribed multiple medications for co-morbid medical conditions or patients with mental health conditions such as anxiety⁵
- It has also been suggested that the use of benzodiazepines may be an indicator for those at high risk of opioid overdose⁶
- It may be safer to taper a patient off opioids (in comparison to benzodiazepines) when jointly prescribed. This method may be more effective given benzodiazepine withdrawal is associated with greater risk, potentially longer withdrawal symptoms and tapering could result in increased anxiety⁵
- Clinicians must advise their patient and/or caregivers about the risks associated with using these medications in combination, or with other CNS depressants such as alcohol²
- Clinicians should also ensure that patients understand the effect their medication may have on their ability to safely drive or operate other machinery, particularly if other CNS depressants are used concomitantly⁵

Further resources

Faculty of Pain Medicine (ANZCA), 'Recommendations regarding the use of Opioid Analgesics in patients with chronic Non-Cancer Pain', <http://fpm.anzca.edu.au/documents/pm1-2010.pdf>

RACGP, 'Prescribing drugs of dependence in general practice, part A: clinical governance framework' <https://www.racgp.org.au/your-practice/guidelines/drugs-of-dependence-a>

RACGP, 'Prescribing drugs of dependence in general practice, part B: benzodiazepines' <https://www.racgp.org.au/your-practice/guidelines/drugs-of-dependence-b>

Primary Health Tasmania, 'A Guide to Deprescribing Benzodiazepines' <https://www.primaryhealthtas.com.au/sites/default/files/A%20Guide%20to%20Deprescribing%20Benzodiazepines.pdf>

Primary Health Tasmania, 'A Guide to Deprescribing Opioids' <https://www.primaryhealthtas.com.au/sites/default/files/A%20Guide%20to%20Deprescribing%20Opioids.pdf>

Beyond Blue, 'Resources for Health Professionals' <https://www.beyondblue.org.au/health-professionals>

Centre for Clinical Interventions, 'Top 10 Patient Handouts for free download by GPs' <http://www.cci.health.wa.gov.au/resources/doctors.cfm>

NPS MedicineWise, 'Chronic pain: opioids and beyond' and 'Chronic pain: opioids and beyond case study' <https://www.nps.org.au/cpd/activities/chronic-pain-opioids-and-beyond?p=GPs> and <https://www.nps.org.au/cpd/activities/chronic-pain-opioids-and-beyond-case-study?p=GPs>

All states and territories across Australia provide a help line for health professionals seeking advice on the treatment of patients with drug issues

VIC (DACAS): 1800 812 804
SA (DACAS): 08 7087 1742

NSW (DASAS): 02 9361 8006
(Syd) or 1800 023 687
(Regional/rural NSW)

TAS (DACAS): 1800 630 093
ACT (Alcohol and Drug Service):
02 6207 9977

Reconnexion: 1300 273 266

To request information, resources or secondary consultations on
benzodiazepine issues

NT (DACAS): 1800 111 092
WA (Drugs of Dependence Unit):
9222 4424

References

1. Australian Bureau of Statistics, 'Drug Induced Deaths in Australia: A changing story', 3303.0- Causes of Death, Australia, 2016. (accessed online 23/7/2018)
(<http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/3303.0~2016~Main%20Features~Drug%20Induced%20Deaths%20in%20Australia~6>)
2. FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics. Updated 05/2017. (accessed online 17/7/2018)
(<https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM515636.pdf>)
3. Webster L. President's Message Eight Principles for Safer Opioid Prescribing. Pain Medicine 2013; 14:959- 961. (accessed online 23/7/18) (<http://onlinelibrary.wiley.com/doi/10.1111/pme.12194/pdf>)
4. Webster LR, Choi Y, Desai H, Grant BJB, Webster L. Sleep-disordered breathing and chronic opioid therapy. Pain Med 2008;9(4):425–32. (<https://www.ncbi.nlm.nih.gov/pubmed/18489633>)
5. Dowell D, Tamara MH, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain – United States 2016. MMWR Recommendations and Reports March 18, 2016; 65(1):1-49 (accessed online 17/7/2018) (<https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6501e1.pdf>)
6. Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med 2015;49:493–501.
(<http://dx.doi.org/10.1016/j.amepre.2015.03.040>)
7. Jann M, Kennedy MK, Lopez, G. Benzodiazepines. A Major Component in Unintentional Prescription Drug Overdoses With Opioid Analgesics. Journal of Pharmacy Practice Vol 27, Issue 1: 5-16.
(<https://doi.org/10.1177/0897190013515001>)
8. Mallick, J., Johnston, J., Goren, N., & Kennedy, V. (2007). Drugs and Driving in Australia: A Survey of Community Attitudes, Experiences and Understanding. Melbourne: Australian Drug Foundation.
9. Chou R, Gordon D, de Leon-Casasola O, et al. Guidelines on the Management of Postoperative Pain: A Clinical Practice Guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. The Journal of Pain 2016; 17 (2) 131-157 ([http://www.jpain.org/article/S1526-5900\(15\)00995-5/pdf](http://www.jpain.org/article/S1526-5900(15)00995-5/pdf))